DOCSLIB.ORG

Combination of Dofetilide and a Calcium Channel Blocker

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combination of Dofetilide and a Calcium Channel Blocker ^ ^ ^ ^ I ^ ^ ^ ^ II ^ II ^ ^ ^ ^ ^ II ^ ^ ^ ^ ^ ^ ^ ^ ^ I ^ � European Patent Office Office europeen des brevets EP 0 965 341 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) |nt C|.6: A61 K 31/44 22.12.1999 Bulletin 1999/51 // (A61 K3i/44> 3-| ;-|8) (21) Application number: 99303489.1 (22) Date of filing: 04.05.1999 (84) Designated Contracting States: (72) Inventors: AT BE CH CY DE DK ES Fl FR GB GR IE IT LI LU • Friedrich, Tilman MC NL PT SE Groton Long Point 06340, Connecticut (US) Designated Extension States: • Billing, Clare B., Jr. AL LT LV MK RO SI Mystic 06355, Connecticut (US) • Falk, Rodney H. (30) Priority: 14.05.1998 US 85496 P Newton 02159, Massachusetts (US) (71) Applicants: (74) Representative: Baillie, lain Cameron • Pfizer Products Inc. Ladas & Parry, Groton, Connecticut 06340 (US) Dachauerstrasse 37 • BOSTON UNIVERSITY 80335 Miinchen (DE) Boston, MA 02215 (US) (54) Combination of dofetilide and a calcium channel blocker (57) Pharmaceutical compositions and methods compositions and methods are useful for the treatment comprising dofetilide and calcium channel blockers. The of arrhythmias. CM < CO lO CO O) o a. LU Printed by Jouve, 75001 PARIS (FR) EP 0 965 341 A2 Description BACKGROUND OF INVENTION 5 [0001] This invention relates to pharmaceutical combination of dofetilide and a calcium channel blocker, kits con- taining such combinations and the use of such combinations to treat atrial fibrillation in mammals. [0002] Dofetilide is a selective inhibitor of the rapid component of the delayed rectifier potassium current which pro- longs the action potential duration and the effective refractory period in a concentration dependent manner. Clinical studies have demonstrated that dofetilide is effective in treating patients with atrial as well as ventricular arrhythmias. 10 Specifically, for example, dofetilide has been studied in patients with severe left ventricular dysfunction (William M. Bailey et al., Electrophysiologic and Hemodynamic Effects of Dofetilide in Patients with Severe Left Ventricular Dys- function, Circulation, 1 992, Vol. 86, Part 4, Supplement 1 , page 1 265) in which it was found that, unlike class I agents, dofetilide is safe in patients with congestive heart failure. [0003] Studies have shown that episodes of atrial fibrillation result in acute shortening of the atrial refractory period. is This is known as "electrical remodeling" of the atrium and is reversible after conversion to sinus rhythm. Prior to com- plete reversal of the decreased refractory period, the atrium has increased vulnerability for relapse to atrial fibrillation. However, Tieleman et al., in A Clinical Illustration of Reduction of Electrical Remodeling by the use of Intracellular Calcium Lowering Drugs During AF, NASPE Abstract, Pace, Vol. 20, page 1142, No. 368, April 1997 concluded "[p] atients using intracellular calcium lowering drugs during AF seem to experience a lower incidence of relapse of AF 20 after cardioversion. This could be explained by a reduction of electrical remodeling of the atria by prevention of intra- cellular calcium overload during AF." In addition, Daoud et al., in Circulation, vol. 96, No. 5, Sept. 1997 "Effect of Ver- apamil and Procainamide on Atrial Fibrillation-Induced Electrical Remodeling in Humans" concluded "pretreatment with the calcium channel antagonist verapamil, but not the sodium channel antagonist procainamide, markedly atten- uates acute, AF-induced changes in atrial electrophysiological properties. These data suggest that calcium loading 25 during AF may be at least partially responsible for AF-induced electrical remodeling." [0004] Amlodipine is a calcium channel blocker that has seen widespread acceptance. It is approved for the treatment of hypertension. Further, U.S. Pat. No. 5,155,120 discloses its use for the treatment of congestive heart failure. [0005] Although there are some therapies for the treatment of atrial fibrillation there is a continuing search in this field of art for new therapies. 30 SUMMARY OF THE INVENTION [0006] This invention is directed to pharmaceutical compositions comprising dofetilide or a pharmaceutical^ accept- able salt thereof and a calcium channel blocker and for the use of such compositions for the treatment of arrhythmia, 35 including atrial fibrillation, in mammals (e.g., humans either male or female). [0007] The combinations comprise therapeutically effective amounts of dofetilide and a calcium channel blocker. [0008] Another aspect of this invention is a method for treating arrhythmias in a mammal comprising administering to a mammal in need of treatment thereof therapeutically effective amounts of 40 a. dofetilide; and b. a calcium channel blocker. [0009] A preferred method is wherein atrial fibrillation is treated. [0010] It is especially preferred that maintenance of normal sinus rhythm is improved. A particularly preferred method 45 is the inhibition of electrical remodeling of the atrium prior to conversion to sinus rhythm. [0011] A particularly preferred mammal is a female or male human. [0012] It is particularly preferred that the human patient has sustained atrial fibrillation. [0013] Another preferred aspect of this method is wherein the calcium channel blocker is administered prior to ad- ministering dofetilide. so [0014] In another aspect of this method the above sequential administration is followed by substantially simultaneous administration of the calcium channel blocker and dofetilide. [0015] Another aspect of this invention is a kit comprising: a. a therapeutically effective amount of dofetilide and a pharmaceutical^ acceptable carrier in a first unit dosage 55 form; b. a therapeutically effective amount of a calcium channel blocker and a pharmaceutical^ acceptable carrier in a second unit dosage form; and c. means for containing said first and second dosage forms. 2 EP 0 965 341 A2 [0016] Another aspect of this invention is a synergistic pharmaceutical composition for improving the maintenance of normal sinus rhythm in a mammal comprising a. dofetilide; and 5 b. a calcium channel blocker, wherein the amount of dofetilide alone and the amount of the calcium channel blocker alone is insufficient to achieve the improved maintenance of normal sinus rhythm if administered alone and wherein the combined effect of the amount of dofetilide and the calcium channel blocker is greater than the sum of the sinus rhythm maintenance 10 effects achievable with individual amounts of the dofetilide and calcium channel blocker; and c. a pharmaceutical^ acceptable diluent or carrier. [0017] Yet another aspect of this invention is a synergistic method for improving the maintenance of normal sinus is rhythm in a mammal comprising administering to such a mammal a. an amount dofetilide; and b. an amount of a calcium channel blocker 20 wherein the amount of dofetilide alone and the amount of the calcium channel blocker alone is insufficient to achieve the improved maintenance of normal sinus rhythm if administered alone and wherein the combined effect of the amount of dofetilide and the calcium channel blocker is greater than the sum of the sinus rhythm maintenance effects achievable with individual amounts of the dofetilide and calcium channel blocker. [0018] In each of the above compositions, methods and kits, a preferred amount of dofetilide is about 0.1 mcg/kg/ 25 day to about 30 mcg/kg/day and an especially preferred amount of dofetilide is about 1 mcg/kg/day to about 15 meg/ kg/day. [0019] In each of the above compositions, methods and kits, a preferred amount of calcium channel blocker is about 0.001 mg/kg/day to about 10 mg/kg/day and an especially preferred amount of calcium channel blocker is about 0.01 mg/kg/day to about 5 mg/kg/day. 30 [0020] In each of the above compositions, methods and kits, especially preferred calcium channel blockers are am- lodipine, nifedipine, isradipine, diltiazem or verapamil or a pharmaceutical^ acceptable salt thereof. [0021] In each of the above compositions, methods and kits, especially preferred calcium channel blockers are am- lodipine, nifedipine or isradipine or a pharmaceutical^ acceptable salt thereof. [0022] In each of the above compositions, methods and kits, an especially preferred calcium channel blocker is 35 amlodipine or a pharmaceutical^ acceptable salt thereof, particularly the besylate salt thereof. [0023] Another aspect of this invention is a method for treating arrhythmias in a mammal comprising administering to a mammal in need of treatment thereof a therapeutically effective amount of amlodipine or a pharmaceutical^ ac- ceptable salt thereof, particularly the besylate salt thereof. [0024] A preferred method is wherein atrial fibrillation is treated. 40 [0025] It is especially preferred that maintenance of normal sinus rhythm is improved. [0026] A particularly preferred method is the inhibition of electrical remodeling of the atrium prior to conversion to sinus rhythm. [0027] A particularly preferred mammal is a female or male human. [0028] A preferred amount of amlodipine is about 0.001 mg/kg/day to about 1 0 mg/kg/day and an especially preferred 45 amount of calcium channel blocker is about 0.01 mg/kg/day to about 5 mg/kg/day. [0029] This invention makes a significant contribution to the field of anti-arrhythmic agents by a new treatment reg- imen: pretreatment of atrial fibrillation patients with an appropriate calcium channel blocker prior to cardioversion (phar- macological or electrical) improves maintenance of sinus rhythm in conjunction with administration
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Dofetilide (Tikosyn): a New Drug to Control Atrial Fibrillation
    CURRENT DRUG THERAPY WALID I. SALIBA, MD Section of Cardiac Electrophysiology and Pacing, CREDIT Department of Cardiology, Cleveland Clinic Dofetilide (Tikosyn): A new drug to control atrial fibrillation ABSTRACT OFETILIDE (Tikosyn), a new antiarrhyth- mic drug, can convert atrial fibrillation Dofetilide, a new class III antiarrhythmic agent, selectively and atrial flutter to sinus rhythm in approxi- blocks a specific cardiac potassium channel, lKr, increasing mately 30% of cases and maintain sinus the effective refractory period of the myocyte and thereby rhythm after electrical or pharmacologic con- terminating reentrant arrhythmias. Given orally, it appears version for up to 1 year in 60% to 70% of to effectively convert atrial fibrillation and atrial flutter to cases, without increasing the risk of sudden sinus rhythm and maintain sinus rhythm after conversion in death in patients at high risk. appropriately selected patients. This paper reviews the Such new drugs are needed, as many of the pharmacology of dofetilide, the evidence of its antiarrhythmic drugs in use up to now have effectiveness, and the appropriate precautions in using it. actually produced higher mortality rates in clinical trials than did placebo, or cause unac- ceptable side effects. KEY POINTS This article reviews the mechanism of action, safety, effectiveness, and clinical use of Dofetilide is generally well tolerated but like other class III dofetilide. drugs can cause torsades de pointes. The risk is dose- dependent and can be minimized by adjusting the dosage • PROBLEMS WITH PREVIOUS DRUGS according to creatinine clearance and QT interval, by excluding patients with known risk factors for long QT A variety of drugs have been used to terminate syndrome and torsades de pointes, and by starting or prevent atrial and ventricular arrhythmias, treatment in an inpatient monitored setting for the first 3 but their safety, efficacy, and tolerability in days.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Safety and Efficacy of Ibutilide in Cardioversion of Atrial Flutter And
    J Am Board Fam Med: first published as 10.3122/jabfm.2011.01.080096 on 5 January 2011. Downloaded from CLINICAL REVIEW Safety and Efficacy of Ibutilide in Cardioversion of Atrial Flutter and Fibrillation Madhuri Nair, MD, Lekha K. George, MD, and Santhosh K. G. Koshy, MD This article reviews the safety and efficacy of ibutilide for use in patients with atrial fibrillation and flut- ter. Ibutilide, a class III antiarrhythmic agent, is primarily used for conversion of atrial flutter and fi- brillation and is a good alternative to electrical cardioversion. Ibutilide has a conversion rate of up to 75% to 80% in recent-onset atrial fibrillation and flutter; the conversion rate is higher for atrial flutter than for atrial fibrillation. It is also safe in the conversion of chronic atrial fibrillation/flutter among patients receiving oral amiodarone therapy. Ibutilide pretreatment facilitates transthoracic defibrilla- tion and decreases the energy requirement of electrical cardioversion by both monophasic and biphasic shocks. Pretreatment with ibutilide before electrical defibrillation has a conversion rate of 100% com- pared with 72% with no pretreatment. Ibutilide is also safe and efficient in the treatment of atrial fibril- lation in patients who have had cardiac surgery, and in accessory pathway–mediated atrial fibrillation where the conversion rate of ibutilide is as high as 95%. There is up to a 4% risk of torsade de pointes and a 4.9% risk of monomorphic ventricular tachycardia. Hence, close monitoring in an intensive care unit setting is warranted during and at least for 4 hours after drug infusion. The anticoagulation strat- egy is the same as for any other mode of cardioversion.(J Am Board Fam Med 2011;24:86–92.) Keywords: Antiarrhythmics, Arrhythmia, Atrial Fibrillation, Cardiovascular Disorders, Cardioversion, Drug Ther- copyright.
    [Show full text]
  • Method and Compositions for the Treatment of Tumors Comprising a Calcium Channel Blocker Compound of the Dlhydropyridlne Class and a Platinum Coordination Compound
    turopaiscnes patentamt European Patent Office © Publication number: 0 221 382 Office europeen des brevets A1 (2) EUROPEAN PATENT APPLICATION © Application number: 86113897.2 © Int. CI.4: A61K 33/24 , ~ //(A61K33/24,31:44) © Date of filing: 07.10.86 © Priority: 10.10.85 US 786321 © Applicant: THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY © Date of publication of application: 5050 Cass Avenue 13.05.87 Bulletin 87/20 Detroit Michigan 48202(US) © Designated Contracting States: @ Inventor: Honn, Kenneth V. AT BE CH DE ES FR GB IT LI LU NL SE 1889 Stanhope Grosse Polnte Woods, Michigan 48236(US) Inventor: Tayior, John D. 1408 Joliet Place Detroit, Michigan 48207(US) Inventor: Onoda, James M. 212 Baker Street No. 203, Royal Oak, Michigan 48067(US) © Representative: Patentanwalte GrUnecker, Kinkeidey, Stockmalr & Partner Maximllianstrasse 58 D-8000 MUnchen 22(DE) «y Method and compositions for the treatment of tumors comprising a calcium channel blocker compound of the dlhydropyridlne class and a platinum coordination compound. (jy The invention relates to compositions for the vherein R, and R2 are methyl groups, R, and R» are treatment of malignant tumors in a mammal which ilkyi or alkyloxyalkylene groups containing I to 8 comprise: :arbdn atoms and R5 and R« are hydrogen or one or (a) a calcium channel blocker compound of wo electron withdrawing substituents; and the dihydropyridine class selected from the group (b) a platinum coordination compound which ^consisting of las antitumor properties in humans wherein the veight ratio of the calcium channel blocker com- x>und to the platinum coordination compound is >etween I and 1000 and 10 to I.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Abstract Materials and Methods Summary
    A human ex-vivo contractility-based assay for the simultaneous prediction of drug-induced inotropic and pro-arrhythmia risk Najah Abi-Gerges, Ashley Alamillo, Phachareeya Ratchada, Guy Page, Yannick Miron, Nathalie Nguyen, Paul E Miller and Andre Ghetti AnaBios Corp., San Diego, CA 92109, USA Contact email: [email protected] Abstract Human ventricular trabeculae-based model predicts Human ventricular trabeculae-based model the torsadogenic potential of dofetilide and d,l-sotalol predicts safety of verapamil Cardiac safety remains the leading cause of drug development discontinuation and withdrawal of post marketing approvals. This has called into question the reliability of current preclinical safety- testing paradigms, which rely predominantly on animal models, and has led to demands for more predictive tools. To this aim, we sought to develop and validate a new ex-vivo human-based model that uses human ventricular trabeculae, paced under tension and Figure 3. Effects of verapamil on Fc parameters in human ex-vivo ventricular combined with continuous recordings of the exerted force of trabeculae. Verapamil decreased the force contraction (Fc). We were especially interested in establishing if of contraction with an IC50 value of 1.46µM, while it had no effect on TR70 and did not this strategy could provide a more predictive approach for induce any ACs or triggered contractions when tested up to 222-fold its fETPC. n=7 assessing both inotropic activity as well as pro-arrhythmia risk. trabeculae. Note that the negative inotropic Since the T-wave recorded in ECG in the clinics marks ventricular effect of verapamil is in line with its known 2+ repolarization and is therefore an electrical measure of the inhibition of Ca channel).
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Phase II Trial of VELCADE® (Bortezomib)
    Phase II Trial of VELCADE® (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme. Protocol Version: Date of Protocol: Original January 22, 2009 Amendment 1 February 14, 2011 Amendment 2 May 31, 2012 Amendment 3 August 1, 2012 Amendment 4 January 09, 2013 Amendment 5 March 13, 2013 Amendment 6 November 19, 2013 Amendment 7 February 11, 2014 Principal Investigator Dr. Albert Lai University of California at Los Angeles VELCADE (bortezomib) for Injection UCLA STUDY PROTOCOL Protocol Number X05303 Phase II Trial of VELCADE® (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme. Protocol Version: Date of Protocol: Original January 22, 2009 Amendment 1 February 14, 2011 Amendment 2 May 31, 2012 Amendment 3 August 1, 2012 Amendment 4 January 09, 2013 Amendment 5 March 13, 2013 Amendment 6 November 19, 2013 Amendment 7 February 11, 2014 Investigator &Study Center: Principal Investigator Co-Principal Investigator Sub-Investigators Sub-Site: *VELCADE is the exclusive trademark of Millennium Pharmaceuticals, Inc., registered in the United States and internationally. CONFIDENTIAL Page 1 of 86 Amendment 7 version dated February 11, 2014 VELCADE (bortezomib) for Injection UCLA Neuro-Oncology Program PROTOCOL SUMMARY Title: Phase II Trial of VELCADE* (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme. Objectives: This phase II study will examine the safety and efficacy of bortezomib in combination with temozolomide/radiation followed by bortezomib and temozolomide for 2 years (24 28-day cycles) in newly-diagnosed patients with glioblastoma.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Sustained-Release Dihydropyridine Formulation
    Europaisches Patentamt European Patent Office ® Publication number: 0 231 026 Office europeen des brevets A1 EUROPEAN PATENT APPLICATION @ Application number: 87101203.5 © lnt.CI.": A 61 K 31/44 A 61 K 9/16, A 61 K 9/22 @ Date of filing: 29.01.87 © Priority: 30.01.86 US 823896 10.12.86 US 940878 ® Applicant: SYNTEX (U.S.A.) INC. 3401 Hillview Avenue P.O. Box 10850 © Date of publication of application : Palo Alto California 94303 (US) 05.08.87 Bulletin 87/32 @ Inventor: Macfarlane, Calum Brechin © Designated Contracting States: Callater House Champfleurie AT BE CH DE ES FR GB GR IT LI LU NL SE Linthgow EH49 6NB Scotland (GB) Selkirk, Alastair Brereton 14 Cramond Glebe Gardens Edinburgh Scotland (GB) Dey, Michael John 17 Ormiston Drive East Calder West Lothian Scotland (GB) @ Representative: Barz, Peter, Dr. et al Patentanwalte Dipl.-lng. G. Dannenberg Dr. P. Weinhold, Dr. D. Gudel Dipl.-lng. S. Schubert, Dr. P. Barz Siegfriedstrasse 8 D-8000 Munchen 40 (DE) The title of the invention has been amended (Guidelines for Examination in the EPO, A-lll, 7.3). © Sustained-release dihydropyridine formulation. © A long acting sustained release pharmaceutical composi- tion for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binder are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter. CO CM o CO CM O. LU Bundesdruckerei Berlin 0 231 026 Description LONG ACTING FORMULATION This invention concerns long acting sustained releas i pharmaceutical compositions and dosage forms for dihydropyridine calcium channel blockers.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]